Variable

AEIIP total population (n = 68)

AEIPF subpopulation (n = 28)



HR (95% CI)

p value

HR (95% CI)

p value


Clinical variables

Age

1.059 (1.007–1.113)

0.025*

1.045 (0.952–1.147)

0.357

FVC %pred

0.985 (0.961–1.008)

0.195

1.023 (0.991–1.057)

0.164

Time from diagnosis to admission, months (median IQR)

1.010 (0.999–1.020)

0.066

1.013 (0.991–1.034)

0.255

Treatment duration from admission, days (median IQR)

0.961 (0.915–1.009)

0.110

0.940 (0.856–1.031)

0.187

Female gender

2.420 (1.166–5.025)

0.018*

NA

NA

Ex smoker

0.631 (0.312–1.279)

0.202

1.120 (0.248–5.054)

0.883

Current smoker

0.000 (5× e^{− 191}  963× e^{177})

0.957

NA

NA

Biomarkers

BGM

1.047 (0.759–1.442)

0.783

0.966 (0.562–1.662)

0.901

C1M

1.277 (0.946–1.714)

0.108

1.449 (0.911–2.316)

0.116

C3M

1.010 (0.722–1.412)

0.955

0.878 (0.486–1.585)

0.665

C4M

1.214 (0.879–1.675)

0.237

1.115 (0.681–1.831)

0.663

C6M

1.042 (0.774–1.406)

0.785

1.160 (0.702–1.915)

0.564

CRPM

0.959 (0.707–1.304)

0.792

0.939 (0.538–1.638)

0.824

ELM7

1.101 (0.798–1.518)

0.559

0.954 (0.559–1.628)

0.862

VCANM

0.636 (0.432–0.937)

0.022*

0.828 (0.446–1.538)

0.551

 The predictive value of clinical variables for mortality following an acute exacerbation of idiopathic interstitial pneumonia (IIP, n = 68) or the subpopulation of idiopathic pulmonary fibrosis (IPF, n = 28) was evaluated by univariate Cox regression. The predictive value of biomarkers measured at time of acute exacerbation for mortality outcome was evaluated by multiple Cox regression adjusting for age and gender for IIP and by univariate Cox regression for IPF. Data are shown as mean hazard ratio (HR) with 95% confidence intervals (CI). HR for biomarkers are shown per one standard deviation (SD) increase in biomarker levels at time of acute exacerbation. Asterisks indicate statistical significance (*p < 0.05)